A carregar...
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment respon...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3031878/ https://ncbi.nlm.nih.gov/pubmed/21122172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt56 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|